group
Cosmetic peptides
Five topical peptides that sit inside cosmetic law rather than outside drug law, taken one at a time: the INCI name, the study each claim rests on, and who ran it.
A cosmetic peptide is a short chain of amino acids formulated into a cream or a serum and applied to the skin. All five covered here carry an INCI name, the standardised ingredient name that appears on a label, which places them inside a body of law written for cosmetics: acetyl hexapeptide-8, palmitoyl pentapeptide-4, acetyl octapeptide-3, copper tripeptide-1 and pentapeptide-3.
That legal position is the most useful thing to know about them, and it separates this page from every other page on this site. A company may lawfully sell these ingredients and may lawfully make claims about how skin looks, because a claim about appearance is a cosmetic claim. The moment a claim describes changing the structure or a function of the body, the same product is a drug and needs an approval it does not have. Two of these five compounds are sold on mechanisms that sit uncomfortably close to that line, and the entries below say where each one falls.
What the law does not require is proof that any of it does anything. The Modernization of Cosmetics Regulation Act of 2022 added registration, product listing, safety substantiation records and adverse event reporting, and it added no efficacy requirement and no pre-market review of an ingredient [15]. So the evidence question has to be asked separately, one compound at a time, and this page asks it: who ran the trial, how many people were in the control arm, and whether the ingredient was tested on its own. Eighteen numbered sources sit behind the answers.
Not medical advice
This page reports what has been documented about a compound. It is not medical advice, not a diagnosis, not a dosing protocol, and not a recommendation to obtain or use anything described here. Talk to a licensed clinician about anything concerning your health. Read the full disclaimer.
Reviewed against editorial standards Updated
The compounds in this group
Each row names what the compound is and what its published work covers. The evidence level is the strongest tier of evidence about that compound for the use it is sold for. It is a single figure for a whole entry rather than a claim by claim grading, so an entry may also describe work that is weaker, or that tested a different route or a different molecule, and each of those carries its own citation in the text. Where a compound's own review has been run, its page grades every claim area separately.
| Compound | Also known as | What the published work covers | Where it stands | Evidence level |
|---|---|---|---|---|
| Acetyl hexapeptide-8 | Argireline, and formerly acetyl hexapeptide-3 | One randomised placebo-controlled trial in 60 subjects with three to one allocation over four weeks, and a 2025 review finding that whether it reaches a neuromuscular junction remains uncertain | A listed cosmetic ingredient, lawfully sold and lawfully advertised on appearance | [Human RCT] |
| Palmitoyl pentapeptide-4 | Matrixyl, Matrixyl 3000, pal-KTTKS | One double-blind split-face trial in 93 women over 12 weeks, authored from a manufacturer's research laboratory, plus permeation work in excised human skin | A listed cosmetic ingredient. No independent trial of the palmitoyl tripeptide-1 and tetrapeptide-7 combination could be found | [Human RCT] |
| Acetyl octapeptide-3 | SNAP-8 | Two published human studies, both of multi-ingredient microneedle patches that pierce the skin barrier. Neither tested this peptide on its own | A listed cosmetic ingredient sold on manufacturer data that has not been published | [Anecdote] |
| GHK-Cu, topical | Copper tripeptide-1, copper peptide serum | One randomised trial with blinded evaluators after laser resurfacing, 13 patients, which found no objective difference. The most-cited supportive paper is a review | A listed cosmetic ingredient, and the lawful form of a molecule sold elsewhere as an injectable | [Human RCT] |
| Pentapeptide-3 | Vialox | A PubMed search for pentapeptide-3 returns no study of it. This site has found no published work on that peptide | A listed cosmetic ingredient, covered here because it is sold, not because there is evidence to report | [Anecdote] |
Why this category sits inside the law rather than outside it
United States law defines a cosmetic by what it is intended to do: an article applied to the body for cleansing, beautifying, promoting attractiveness or altering the appearance. It defines a drug separately, by an intention to affect the structure or any function of the body, or to treat or prevent disease [16]. The same jar of cream falls on one side or the other depending on what the seller says about it, which is why claim wording, not chemistry, is what makes a cosmetic peptide lawful.
The Modernization of Cosmetics Regulation Act of 2022 was enacted on 29 December 2022 as part of Public Law 117-328 [15]. It added a new subchapter to the Federal Food, Drug, and Cosmetic Act covering facility registration and product listing, safety substantiation, and serious adverse event reporting and record keeping [16]. Labelling requirements for cosmetics sit in their own regulations at 21 CFR part 701 [17].
None of that is an efficacy requirement. A company must register, must list its products, and must hold records adequate to substantiate the safety of what it sells. It does not have to show a regulator that a product does what the advertising says, and no agency reviews the ingredient before it goes on sale [15] [16]. That is the gap this page exists to fill, and it is why the entries below are organised around who ran each study rather than around what each study concluded.
Two mechanisms, and the shared core nobody mentions
Two of these compounds are sold on a nerve-signalling mechanism. Acetyl hexapeptide-8 is patterned on the end of a protein called SNAP-25, part of the SNARE complex that nerve endings assemble to release their signal, and the proposal is that it interferes with that assembly [2] [3]. Acetyl octapeptide-3 is an eight amino acid extension of the same idea. Both are described in marketing as topical alternatives to an injected muscle relaxant, and both face the same physical objection: a hydrophilic peptide of that size does not readily cross an intact stratum corneum, and a 2025 review states that whether acetyl hexapeptide-8 reaches a neuromuscular junction remains uncertain [1].
The other two work on the matrix rather than the nerve. Palmitoyl pentapeptide-4 is a fragment of type I collagen with a fatty acid attached to help it cross skin, and the proposal is that the fragment signals a fibroblast to lay down more matrix [4] [14]. Copper tripeptide-1 is a naturally occurring tripeptide carrying a copper ion, proposed to act on the same remodelling machinery [11] [12].
There is a connection between those two that the marketing on both sides leaves out. The Matrixyl 3000 blend pairs palmitoyl pentapeptide-4 with palmitoyl tripeptide-1, and palmitoyl tripeptide-1 is the glycyl-histidyl-lysine tripeptide with a fatty acid on it: the same tripeptide core as copper tripeptide-1, without the copper. Anyone comparing a Matrixyl 3000 product against a copper peptide serum is comparing two products that share an ingredient family. That shared family appears in the advertising for neither.
What to look for in a cosmetic peptide trial
Four questions separate the trials on this page from each other, and all four are answerable from the abstract. Who employed the authors, because several of these studies were run by the company selling the ingredient or a product containing it. How many people were in the control arm, which is not the same as how many were enrolled. Whether the peptide was tested on its own or inside a formulation carrying half a dozen other actives. And whether the outcome was measured by an instrument or a blinded grader, or reported by the subject.
That last distinction decides the single most informative result in this category. In the copper peptide trial below, the instrument measurements and the blinded evaluators found nothing, and the only endpoint that separated was the patients' own satisfaction questionnaire [10]. Both results are real. They are answers to different questions, and a page that quotes one without the other is not reporting the study.
The five compounds, one at a time
Acetyl hexapeptide-8
Also known as Argireline, Acetyl hexapeptide-3
Plain-English version: A six amino acid peptide applied to the skin, patterned on part of the machinery nerve endings use to release their signal.
Strongest evidence, and what it covers [Human RCT] appearance of expression lines from a topical hexapeptide [1] [2] [3] [13]
Argireline is the trade name for acetyl hexapeptide-8, formerly acetyl hexapeptide-3 under the older nomenclature; both names still appear on labels for the same ingredient. Acetyl hexapeptide-8 is patterned on the N-terminal end of SNAP-25, part of the SNARE complex, and the proposed mechanism is interference with that assembly, the same machinery an injected botulinum toxin acts on at a far higher potency [2] [3]. It is not botulinum toxin and it is not injected, so the comparison people search for is a marketing frame, not an equivalence.
The strongest efficacy study is a randomised, placebo-controlled trial in 60 Chinese subjects with periorbital wrinkles. Allocation was three to one in favour of the active arm, so roughly 15 people received placebo, and the study ran four weeks. Subjective assessment reported a total anti-wrinkle response of 48.9 percent in the active group against 0 percent on placebo, and silicone replicas analysed by a wrinkle-analysis instrument showed decreased roughness parameters in the active group (p below 0.01) with no significant decrease on placebo [2]. A 2025 review of the ingredient's permeability and efficacy concludes that its low skin penetration limits its bioavailability and that whether it reaches neuromuscular junctions remains uncertain [1].
Where it stands A listed cosmetic ingredient under its INCI name. Facility registration, product listing, safety substantiation and serious adverse event reporting apply to any US product containing it under the subchapter added by the Modernization of Cosmetics Regulation Act of 2022 [15] [16], and cosmetic labelling requirements sit at 21 CFR part 701 [17]. No pre-market approval of the ingredient exists and no efficacy substantiation is required.
Our takeThe trial is real, randomised and placebo-controlled, and it rests on about fifteen placebo subjects over four weeks. Set that beside a review published twelve years later still asking whether the molecule gets far enough into skin to do the thing it is sold for.
Palmitoyl pentapeptide-4
Also known as Matrixyl, Matrixyl 3000, pal-KTTKS
Plain-English version: A five amino acid piece of collagen with a fatty tail attached to help it cross skin, and one of the most widely used cosmetic peptides there is.
Strongest evidence, and what it covers [Human RCT] appearance of fine lines from a topical collagen fragment [4] [5] [6] [7] [14]
Palmitoyl pentapeptide-4 is written pal-KTTKS: the amino acids lysine, threonine, threonine, lysine, serine, taken from type I collagen, with palmitic acid attached at the front. The fatty acid is there for a physical reason. The bare pentapeptide is water-loving and does not cross the outer layer of skin well, and attaching a lipid tail is the standard way of improving that. Matrixyl is the trade name for the pentapeptide alone; Matrixyl 3000 is a blend that adds palmitoyl tripeptide-1 and tetrapeptide-7.
The trial the whole ingredient rests on was published in 2005. Ninety-three white women aged 35 to 55 took part in a 12-week, double-blind, placebo-controlled, split-face, left-right randomised study comparing a moisturiser against the same moisturiser carrying the pentapeptide at 3 parts per million. The active side showed significant reduction in wrinkles and fine lines against the control side by both instrumental image analysis and expert grader assessment, and subjects reported the same in self-assessment [4]. Every author's stated affiliation is a consumer products manufacturer's research laboratory, which does not make the result wrong and does make it a single source without independent replication.
Searching for a trial of the palmitoyl tripeptide-1 and tetrapeptide-7 blend returns nothing. No independent randomised trial of that blend, or of the related proprietary mixtures built on palmitoyl tripeptide-5, could be found in the published literature for this page. The nearest thing is a pair of split-face studies of finished anti-ageing products containing the peptides alongside niacinamide, carnosine and retinyl propionate, in 42 and 35 subjects, again authored from a manufacturer [5]. Those studies tested products, not ingredients, and no arm isolated the peptide.
The permeation question has been examined separately and is worth knowing before reading any of the above. In excised human skin, the palmitoylated form was more stable in skin homogenate than the bare pentapeptide, and both showed limited passive permeation [6]. A separate laboratory study measured passive delivery of pal-KTTKS across full-thickness human skin and then measured it again with microneedles piercing the barrier, reporting a 2 to 22 fold signal improvement with the barrier breached [7]. Those are measurements in excised tissue and cell-free systems, and what they establish is how much of the difficulty is physical.
Where it stands A listed cosmetic ingredient under its INCI name, with the same MoCRA duties and the same absence of pre-market ingredient review as every other entry on this page [15] [16] [17].
Our takeOne trial, twenty-one years old, run by the people selling it, and it is still the best evidence in this category by a distance. The blend that outsells the single ingredient has no independent trial at all.
Acetyl octapeptide-3
Also known as SNAP-8
Plain-English version: An eight amino acid extension of the acetyl hexapeptide-8 sequence, sold as the stronger version of it.
Strongest evidence, and what it covers [Anecdote] appearance of expression lines from a topical octapeptide [1] [3] [8] [9]
SNAP-8 is the trade name for acetyl octapeptide-3, an eight amino acid peptide built as an extension of the acetyl hexapeptide-8 sequence and sold on the same SNARE-complex reasoning. The marketing position is straightforward: same mechanism, longer chain, more potency.
A PubMed search for acetyl octapeptide-3 returns two records, and neither of them tests the peptide on its own. The first is a clinical evaluation of a dissolving microneedle patch containing hyaluronic acid, acetyl octapeptide-3, an ascorbic acid derivative and a lysophosphatidic acid salt, in 24 subjects, with a hyaluronic-acid-only patch as the comparator on the other eye [8]. The second is a monocentric 12-week study of hyaluronic acid microneedle patches carrying an arginine and lysine polypeptide, acetyl octapeptide-3, palmitoyl tripeptide-5, adenosine and seaweed extracts, with no placebo arm at all [9].
Two things follow, and both matter more than the results either study reported. Neither design can attribute anything to acetyl octapeptide-3, because in each case the peptide arrived inside a mixture and the comparator differed by more than one ingredient. And the delivery method in both is a microneedle patch, which physically punctures the stratum corneum. That is the barrier the whole permeability argument in this category is about. A peptide delivered through holes made in the skin is not evidence about the same peptide in a cream, and the review of the closely related hexapeptide makes exactly this point about topical delivery [1].
Which leaves the potency claim. Every comparative statement in circulation about acetyl octapeptide-3 against acetyl hexapeptide-8 traces to unpublished supplier data rather than to a study anyone can read, and no head to head between the two has been published. The class reviews describe the mechanism and do not resolve the comparison [1] [3]. That is the tier this entry carries, and it is not a comment on whether the ingredient does anything: it is a statement about what is available to check.
Where it stands A listed cosmetic ingredient under its INCI name, carrying the same MoCRA registration, listing, safety substantiation and adverse event duties as every other entry here [15] [16] [17]. No agency has reviewed it for effect, and none is required to.
Our takePubMed has two records for this ingredient and both are patch studies that pierce the skin. An ingredient sold specifically as the one that gets through skin better has no published test of it getting through skin.
GHK-Cu, topical
Also known as Copper tripeptide-1, Copper peptide serum
Plain-English version: The same copper-carrying tripeptide sold elsewhere as an injectable, in the form where it is a listed cosmetic ingredient.
Strongest evidence, and what it covers [Human RCT] appearance and healing of skin from a topical copper tripeptide [10] [11] [12] [14] [18]
Copper tripeptide-1 is the INCI name for GHK-Cu: glycyl-histidyl-lysine bound to a copper ion. The tripeptide occurs naturally in human plasma, and it is the same molecule that appears elsewhere in this catalogue as an injectable. The distinction is entirely legal and it is not a small one. Applied to skin and sold on appearance, it is a cosmetic ingredient with a name on a label. Put in a vial for injection and sold for repair, it is an unapproved drug.
Two independent randomised trials of the topical form have been published and both came back the same way on their objective measures. The larger came first: in 1992, 86 evaluable patients with venous stasis ulcers were randomised, evaluator-blinded, to a tripeptide copper complex cream at 0.4 percent, silver sulfadiazine 1 percent, or an inert vehicle. The copper arm did not differ from the vehicle, while silver sulfadiazine in the same trial reduced ulcer size against both [18]. The second is worth setting out in full because of how it was designed. Patients underwent circumoral skin resurfacing with a carbon dioxide laser at standard settings, then were randomised to a post-treatment skin regimen with or without the copper tripeptide. Thirteen patients completed. Computer analysis and blinded evaluators found no statistically significant difference between the groups for resolution of redness. All patients had significant improvement in wrinkles and overall skin quality, and no difference was found between the groups. The one endpoint that did separate was a validated patient questionnaire, on which satisfaction with overall skin quality was significantly higher in the copper group (p equals 0.04) [10].
That split is the most instructive result on this page. Blinded evaluators and instruments saw nothing; the people using the product reported a difference. Both measurements are legitimate and they answer different questions, and a page reporting either one alone would be misrepresenting the study. Thirteen patients is also a small trial, and a small trial that finds nothing has not established that there is nothing to find. This ingredient now has a full evidence review of its own on this site, graded B, which sets out both trials and the FDA compounding record behind the injectable form.
The paper cited most often in support of copper peptides is not a trial. It is a 2008 review of the tripeptide and tissue remodelling, running through chemoattraction of repair cells, protein synthesis, proliferation and a long list of related processes, and the corresponding author's stated affiliation is a company selling copper peptide skin products rather than a university department [11]. A 2025 review of topically applied GHK as an anti-wrinkle peptide sets out the same mechanistic case alongside the delivery problems that come with it [12]. Neither is a controlled trial, and under this site's rules a review inherits the tier of the work it pools rather than earning a higher one.
Where it stands Copper tripeptide-1 is a listed cosmetic ingredient, and a topical product containing it carries MoCRA facility registration, product listing, safety substantiation and adverse event duties [15] [16] with labelling under 21 CFR part 701 [17]. The injectable form of the same molecule has no approval of any kind, and the difference between the two is the intended use the seller states, not the chemistry [16].
Our takeTwo trials blinded their assessors and both found nothing, and the only endpoint that moved was the one the patients filled in themselves. That is a genuinely interesting result about cosmetics generally, and it is not the result the ingredient is sold on.
Pentapeptide-3
Also known as Vialox
Plain-English version: Pentapeptide-3, a five amino acid cosmetic peptide sold on muscle-relaxing reasoning, with no published study of that peptide behind it.
Strongest evidence, and what it covers [Anecdote] appearance of expression lines from a topical pentapeptide [3] [13] [16] [17]
Vialox is the trade name for pentapeptide-3, a listed cosmetic ingredient that appears in serums sold on the same expression-line premise as Argireline and SNAP-8. Pentapeptide-3 is in the catalogue for one reason: it is on sale, and this site covers every compound it lists rather than only the ones with a literature.
A PubMed search on the ingredient name returns six records and not one of them is about this cosmetic ingredient. The hits are unrelated pentapeptides: analogues of an amyloid fragment, analogues of the type I collagen sequence covered above, angiotensin fragments and renin inhibitors. Three further searches were run for this page and returned nothing at all: the trade name with the word cosmetic, the ingredient name with skin and wrinkle, and the mechanism terms alongside the other muscle-relaxing peptides in this category. So this page has found no published study of pentapeptide-3 as a cosmetic ingredient, no permeation measurement, and no trial of any design.
So no mechanism is described for it here. A mechanism can be read off a related compound and stated as an inference, and doing that for this ingredient would put a sentence on the page that no source supports, which is the specific failure the reviews of this category keep flagging in cosmetic marketing copy [3] [13]. What can be said is where it sits legally, which is the same place as the other four: a cosmetic ingredient, lawfully sold, whose seller must hold safety substantiation records and must not make a structure or function claim about it [16] [17].
Where it stands A listed cosmetic ingredient. Any US product containing it is subject to facility registration, product listing, safety substantiation and serious adverse event reporting [16], with labelling under 21 CFR part 701 [17]. As with every ingredient on this page, nothing in that framework requires evidence that it does anything.
Our takeFive compounds went into this page and four of them had something to read. This one has a label, a trade name and a price list, and the honest entry for it is this short.
What we do not know about this group
No trial on this page tested a cosmetic peptide against another cosmetic peptide. Every comparative claim in this category, including the potency ranking between acetyl hexapeptide-8 and acetyl octapeptide-3, rests on supplier material rather than on a published head to head.
Skin penetration is unresolved for the two nerve-signalling peptides and only partly characterised for the collagen fragment. A 2025 review states plainly that whether acetyl hexapeptide-8 reaches a neuromuscular junction remains uncertain [1], and the permeation work on pal-KTTKS was done in excised skin with the barrier intact and then deliberately breached [6] [7]. What crosses living facial skin from a marketed formulation has not been measured for any of these five.
Duration has not been studied. The longest trial here ran 12 weeks [4], and nothing in the published record describes what happens to skin after a year of continuous use of any of these ingredients, or what happens when use stops.
The trials that exist are small and most were run by an interested party. Ninety-three subjects is the largest active arm on this page; the copper tripeptide trial completed 13 patients [10]; the acetyl hexapeptide-8 trial allocated roughly 15 to placebo [2]. Independent replication does not exist for any of the five.
Nothing has been published at all on pentapeptide-3 as a cosmetic ingredient. That is not a weak evidence base, it is an absent one, and the entry above says so rather than filling the space with a mechanism borrowed from a neighbour.
What this evidence can and cannot show
These results come from excised human skin, skin homogenates and cell preparations in laboratory permeation and stability systems, not from people. An animal model is a deliberate simplification: the injury is created on purpose, the animal is young and healthy, the dose is scaled to body weight in a way that does not translate directly, and the outcome is measured at a fixed point rather than lived with. Cell and tissue work is a further step removed, because the concentrations that produce an effect in a dish are often far above anything a body reaches. Mechanism is a reason to run a trial. It is not a substitute for one, and compounds that looked mechanistically convincing have failed in people many times.
Frequently asked questions
Are cosmetic peptides legal to sell in the United States?
Yes, and that is what separates them from most compounds on this site. They are listed cosmetic ingredients, and a product containing one may be sold provided the seller registers the facility, lists the product, holds safety substantiation records and reports serious adverse events. Claims must be about appearance rather than about changing a structure or function of the body.
Does anyone check that a cosmetic peptide does anything before it goes on sale?
No. The Modernization of Cosmetics Regulation Act of 2022 added registration, listing, safety substantiation and adverse event duties. It created no pre-market approval step for a cosmetic ingredient and no requirement to substantiate an efficacy claim to a regulator.
Is Argireline the same as an injected muscle relaxant?
No. Acetyl hexapeptide-8 is a six amino acid peptide patterned on part of the SNARE complex, applied to the skin, at a potency nowhere near that of a botulinum toxin, and a 2025 review still describes it as uncertain whether it reaches a neuromuscular junction at all. The comparison is a marketing frame.
What is the difference between Matrixyl and Matrixyl 3000?
Matrixyl is palmitoyl pentapeptide-4 on its own. Matrixyl 3000 adds palmitoyl tripeptide-1 and tetrapeptide-7. The 2005 split-face trial that the ingredient is known for tested the single pentapeptide at 3 parts per million, and no independent trial of the palmitoyl tripeptide-1 and tetrapeptide-7 blend could be found for this page.
Is topical GHK-Cu the same molecule as injectable GHK-Cu?
Yes, the molecule is the same tripeptide bound to copper. What differs is the legal position and the evidence attached to each route. As copper tripeptide-1 in a serum it is a listed cosmetic ingredient; in a vial for injection it is an unapproved drug, and the studies behind each route are not interchangeable.
Why does the copper peptide trial get described as both positive and negative?
Because it was both, on different endpoints. Instrument measurements and blinded evaluators found no significant difference after laser resurfacing across 13 patients. The patients' own satisfaction questionnaire did separate, at p equals 0.04. Quoting either result without the other misrepresents the study.
Do microneedle patch studies count as evidence for a peptide in a cream?
They answer a different question. A microneedle patch punctures the outer layer of skin, which is the barrier the entire permeability debate in this category is about. Both published studies naming acetyl octapeptide-3 used patches and both delivered several actives at once, so neither can attribute a result to that peptide in a topical formulation.
What is an INCI name and why does it matter here?
It is the standardised ingredient name that appears in a cosmetic ingredient list, which is why the same compound has a trade name in the advertising and a different name on the back of the box. Argireline is acetyl hexapeptide-8, Matrixyl is palmitoyl pentapeptide-4, SNAP-8 is acetyl octapeptide-3 and Vialox is pentapeptide-3. Reading the INCI name is how you tell what you are actually buying.
Why did acetyl hexapeptide-3 become acetyl hexapeptide-8?
The international nomenclature for the ingredient was revised, and the compound is the same. Both names remain in circulation on labels and in search results, which makes this one of the easier alias traps in the category to fall into.
References
- Zdrada-Nowak J, Surgiel-Gemza A, Szatkowska M. Acetyl Hexapeptide-8 in Cosmeceuticals-A Review of Skin Permeability and Efficacy. Int J Mol Sci. 2025. PMID 40565185 DOI 10.3390/ijms26125722
- Wang Y, Wang M, Xiao S, Pan P, Li P, Huo J. The anti-wrinkle efficacy of argireline, a synthetic hexapeptide, in Chinese subjects: a randomized, placebo-controlled study. Am J Clin Dermatol. 2013. PMID 23417317 DOI 10.1007/s40257-013-0009-9
- Skibska A, Perlikowska R. Signal Peptides - Promising Ingredients in Cosmetics. Curr Protein Pept Sci. 2021. PMID 34382523 DOI 10.2174/1389203722666210812121129
- Robinson LR, Fitzgerald NC, Doughty DG, Dawes NC, Berge CA, Bissett DL. Topical palmitoyl pentapeptide provides improvement in photoaged human facial skin. Int J Cosmet Sci. 2005. PMID 18492182 DOI 10.1111/j.1467-2494.2005.00261.x
- Kaczvinsky JR, Griffiths CE, Schnicker MS, Li J. Efficacy of anti-aging products for periorbital wrinkles as measured by 3-D imaging. J Cosmet Dermatol. 2009. PMID 19735523 DOI 10.1111/j.1473-2165.2009.00444.x
- Choi YL, Park EJ, Kim E, Na DH, Shin YH. Dermal Stability and In Vitro Skin Permeation of Collagen Pentapeptides (KTTKS and palmitoyl-KTTKS). Biomol Ther (Seoul). 2014. PMID 25143811 DOI 10.4062/biomolther.2014.053
- Mohammed YH, Yamada M, Lin LL, Grice JE, Roberts MS, Raphael AP, Benson HA, Prow TW. Microneedle enhanced delivery of cosmeceutically relevant peptides in human skin. PLoS One. 2014. PMID 25033398 DOI 10.1371/journal.pone.0101956
- Shin JY, Han D, Yoon KY, Jeong DH, Park YI. Clinical Safety and Efficacy Evaluation of a Dissolving Microneedle Patch Having Dual Anti-Wrinkle Effects With Safe and Long-Term Activities. Ann Dermatol. 2024. PMID 39082657 DOI 10.5021/ad.23.136
- Avcil M, Akman G, Klokkers J, Jeong D, Çelik A. Efficacy of bioactive peptides loaded on hyaluronic acid microneedle patches: A monocentric clinical study. J Cosmet Dermatol. 2020. PMID 31134751 DOI 10.1111/jocd.13009
- Miller TR, Wagner JD, Baack BR, Eisbach KJ. Effects of topical copper tripeptide complex on CO2 laser-resurfaced skin. Arch Facial Plast Surg. 2006. PMID 16847171 DOI 10.1001/archfaci.8.4.252
- Pickart L. The human tri-peptide GHK and tissue remodeling. J Biomater Sci Polym Ed. 2008. PMID 18644225 DOI 10.1163/156856208784909435
- Mortazavi SM, Mohammadi Vadoud SA, Moghimi HR. Topically applied GHK as an anti-wrinkle peptide: Advantages, problems and prospective. Bioimpacts. 2025. PMID 39963574 DOI 10.34172/bi.30071
- Ramos-e-Silva M, Celem LR, Ramos-e-Silva S, Fucci-da-Costa AP. Anti-aging cosmetics: facts and controversies. Clin Dermatol. 2013. PMID 24160281 DOI 10.1016/j.clindermatol.2013.05.013
- Pintea A, Manea A, Pintea C, Vlad RA, Bîrsan M, Antonoaea P, Rédai EM, Ciurba A. Peptides: Emerging Candidates for the Prevention and Treatment of Skin Senescence: A Review. Biomolecules. 2025. PMID 39858482 DOI 10.3390/biom15010088
- United States Congress. Consolidated Appropriations Act, 2023, Public Law 117-328, enacted 29 December 2022. Division FF, title III, subtitle E is the Modernization of Cosmetics Regulation Act of 2022, which adds subchapter VI of the Federal Food, Drug, and Cosmetic Act. govinfo. 2022. Source document
- Office of the Law Revision Counsel, United States House of Representatives. Federal Food, Drug, and Cosmetic Act, title 21 of the United States Code: section 321 for the definitions of drug and cosmetic, and subchapter VI sections 364 to 364d for cosmetic definitions, adverse events, registration and product listing, and safety substantiation. Checked 2 August 2026. United States Code. 2026. Source document
- Office of the Federal Register and Government Publishing Office. Cosmetic labeling, title 21 of the Code of Federal Regulations, part 701. Checked 2 August 2026. Electronic Code of Federal Regulations. 2026. Source document
- Bishop JB, Phillips LG, Mustoe TA, VanderZee AJ, Wiersema L, Roach DE, Heggers JP, Hill DP Jr, Taylor EL, Robson MC. A prospective randomized evaluator-blinded trial of two potential wound healing agents for the treatment of venous stasis ulcers. J Vasc Surg. 1992. PMID 1495150 DOI 10.1067/mva.1992.37086